SHAPIRO LEE
Known title: DirectorCIK: 0001213350
SHAPIRO LEE's purchase track record
SHAPIRO LEE has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/11/2022 | CLOV | $248K | -27.5% | -15.2% | -3.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CLOV | ▲ Buy | Grant | 60,975 | $0 | 1/6/2025 | View on chart |
| CLOV | ▲ Buy | Grant | 206,185 | $200K | 1/3/2024 | View on chart |
| CLOV | ▲ Buy | Grant | 176,991 | $0 | 1/3/2023 | View on chart |
| CLOV | ▲ Buy | Option Exercise | 27,100 | $0 | 9/22/2022 | View on chart |
| CLOV | ▲ Buy | Grant | 20,271 | $0 | 9/22/2022 | View on chart |
| CLOV | ▲ Buy | Open Market | 80,000 | $248K | 3/11/2022 | View on chart |
| CLOV | ▲ Buy | Option Exercise | 27,100 | $0 | 1/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Clover Health Gains After Earning 5-Star CMS Rating
Clover Health stock rose after the company secured a 5-star rating for its PPO plan from CMS for 2027. This top score supports the company's long-term outlook and may help attract new members. The news follows a period where the stock was trading near its 52-week high, reflecting positive market sentiment.
Clover Health Gains After Earning 5-Star CMS Rating. Clover Health stock rose after the company secured a 5-star rating for its PPO plan from CMS for 2027. This top score supports the company's long-term outlook and may help attract new members. The news follows a period where the stock was trading near its 52-week high, reflecting positive market sentiment.